Amphastar Pharmaceuticals, Inc. has entered into an Asset Purchase Agreement with Eli Lilly and Company to acquire BAQSIMI glucagon nasal powder and related assets for $500 million in cash, with additional contingent consideration of up to $450 million based on certain milestones.